Lv52
910 积分 2025-10-20 加入
Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
2个月前
已完结
Wake Up and Smell the Fusions: Single-Modality Molecular Testing Misses Drivers
2个月前
已完结
First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report
3个月前
已完结
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
3个月前
已完结
Two rare exon 21 EGFR mutations in patients treated with gefitinib
3个月前
已完结
Two rare ALK fusion variants overlooked by multiplexed gene testing: The crucial role of immunohistochemistry in ensuring comprehensive molecular testing
4个月前
已完结
NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting
4个月前
已完结
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands
4个月前
已完结
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers
6个月前
已完结
First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation
8个月前
已完结
皖公网安备34019202002308
